Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo

被引：0
|
作者：
Kirsten Dettmar
Isabell Seitz-Merwald
Carsten Lindemann
Petra Schroeder
Diane Seimetz
Judith Atz
机构：
[1] Fresenius Biotech GmbH,
[2] EUFETS GmbH,undefined
来源：
Clinical and Translational Oncology | 2012年 / 14卷
关键词：
Catumaxomab; Trifunctional antibody; T lymphocyte; Endothelium; Adhesion; Redistributi;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：376 / 381
页数：5
相关论文
共 50 条
  • [21] The trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with malignant ascites: Immunomonitoring results of a pivotal phase II/III study (pooled population)
    Jaeger, M.
    Schoberth, A.
    Hennig, M.
    Burges, A.
    Heiss, M.
    Wimberger, P.
    Schmalfeldt, B.
    Lindhofer, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Immunomonitoring results of a pivotal phase II/III study with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in ovarian cancer patients with malignant ascites
    Jaeger, M. J.
    Schoberth, A. M.
    Heiss, M. M.
    Lahr, A.
    Lindhofer, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Treatment of non-small cell lung cancer (NSCLC) patients with the trifunctional bispecific antibody catumaxomab (removab®) (anti-EpCAM x anti-CD3:: Results of a phase I study
    Sebastian, M
    Schmittel, A
    Friccius-Quecke, H
    Kanniess, F
    Wiewrodt, R
    Lindhofer, H
    Jaeger, M
    Passlick, B
    LUNG CANCER, 2005, 49 : S376 - S376
  • [24] An evaluation of anti-EpCAM x anti-CD3 bispecific antibody using patients derived cancer organoids.
    Tsumura, Ryo
    Komatsu, Teruo
    Koga, Yoshikatsu
    Yasunaga, Masahiro
    CANCER SCIENCE, 2025, 116 : 300 - 300
  • [25] Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.
    Qi, Changsong
    Wu, Shikai
    Kim, In-Ho
    Cai, Shirong
    Wang, Jufeng
    Kim, Seung Tae
    Wang, Jaw-Yuan
    Bai, Li-Yuan
    Lin, Cheng-Yao
    Liang, Zhezhao
    Wei, Jian Xin
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16102 - E16102
  • [26] A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy
    Frey, Gerhard
    Cugnetti, Ana Paula G.
    Liu, Haizhen
    Xing, Charles
    Wheeler, Christina
    Chang, Hwai Wen
    Boyle, William J.
    Short, Jay M.
    MABS, 2024, 16 (01)
  • [27] Updated results of a phase II trial evaluating an anti-EpCAM x anti-CD3 bispecific antibody, M701, for the treatment of malignant ascites
    Liu, R.
    Xu, J.
    Lin, R.
    Li, N.
    Li, G.
    Zhang, T.
    Zhao, J.
    Li, J.
    Sun, M.
    Wang, K.
    An, H.
    Zhang, W.
    Xu, H.
    Zeng, S.
    Zhang, M.
    Zhou, P.
    Huang, S.
    Wang, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S1427 - S1428
  • [28] Tolerability and efficacy of the trifunctional antibody removab® (anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study
    P Wimberger
    A Burges
    V Gorbounova
    H Sommer
    B Schmalfeldt
    J Pfisterer
    M Lichinitser
    A Makhson
    M Ströhlein
    W Eiermann
    M Biakhov
    V Moiseenko
    A du Bois
    R Kimmig
    Cancer Cell International, 4 (Suppl 1)
  • [29] An anti-EpCAM x anti-CD3 bispecific antibody, M701, for the treatment of malignant ascites due to epithelial cancer: Interim results of a prospective randomized controlled phase II trial
    Lin, Rongbo
    Xu, Jianming
    Liu, Rongrui
    Li, Ning
    Li, Guiling
    Zhang, Tao
    Zhao, Jun
    Li, Jiayi
    Sun, Meili
    Wang, Ke
    An, Hanxiang
    Zhang, Weijie
    Xu, Huiting
    Zeng, Shan
    Zhang, Mingjun
    Zhou, Pengfei
    Huang, Shaoyi
    Wang, Xiong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Intraperitoneal immunotherapy with the bispecific anti-EpCAM x anti-CD3 directed antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer: Final results of a randomized phase II AIO trial.
    Lordick, Florian
    Kunzmann, Volker
    Trojan, Jorg
    Daum, Severin
    Schenk, Michael
    Kullmann, Frank
    Schroll, Sebastian
    Behringer, Dirk M.
    Stahl, Michael
    Al-Batran, Salah-Eddin
    Ibach, Stefan
    Koerfer, Justus
    Knoedler, Maren Kristina
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345